Able 0 4 0 4 B-language_fluency
to 5 7 5 7 I-language_fluency
read 8 12 8 12 I-language_fluency
or 13 15 13 15 I-language_fluency
understand 16 26 16 26 I-language_fluency
English 27 34 27 34 I-language_fluency
- 34 35 34 35 O
this 35 39 35 39 O
is 40 42 40 42 O
included 43 51 43 51 O
because 52 59 52 59 O
the 60 63 60 63 O
intervention 64 76 64 76 O
and 77 80 77 80 O
study 81 86 81 86 O
materials 87 96 87 96 O
( 97 98 97 98 O
including 98 107 98 107 O
outcome 108 115 108 115 O
measures 116 124 116 124 O
) 124 125 124 125 O
are 126 129 126 129 O
only 130 134 130 134 O
in 135 137 135 137 O
English 138 145 138 145 O

Patients 0 8 146 154 O
diagnosed 9 18 155 164 O
with 19 23 165 169 O
hematologic 24 35 170 181 O
( 36 37 182 183 O
as 37 39 183 185 O
a 40 41 186 187 O
population 42 52 188 198 O
distinct 53 61 199 207 O
from 62 66 208 212 O
solid 67 72 213 218 B-cancer
tumors 73 79 219 225 I-cancer
and 80 83 226 229 O
different 84 93 230 239 O
trials 94 100 240 246 O
) 100 101 246 247 O
cancers 102 109 248 255 B-cancer

Patients 0 8 256 264 O
diagnosed 9 18 265 274 O
with 19 23 275 279 O
solid 24 29 280 285 B-cancer
tumors 30 36 286 292 I-cancer
who 37 40 293 296 O
are 41 44 297 300 O
eligible 45 53 301 309 O
for 54 57 310 313 O
participation 58 71 314 327 O
in 72 74 328 330 O
Phase 75 80 331 336 O
I 81 82 337 338 O
clinical 83 91 339 347 O
trials 92 98 348 354 O
of 99 101 355 357 O
investigational 102 117 358 373 B-treatment
cancer 118 124 374 380 I-treatment
therapies 125 134 381 390 I-treatment

Patients 0 8 391 399 O
who 9 12 400 403 O
have 13 17 404 408 O
signed 18 24 409 415 O
an 25 27 416 418 O
informed 28 36 419 427 O
consent 37 44 428 435 O
for 45 48 436 439 O
participation 49 62 440 453 O
in 63 65 454 456 O
Phase 66 71 457 462 B-treatment
I 72 73 463 464 I-treatment
clinical 74 82 465 473 I-treatment
trials 83 89 474 480 I-treatment

